metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone
	ESCORT, 2020 Lancet Oncol. 2020; : NCT03099382	RCT	mEC - 2nd line (L2)	camrelizumab	docetaxel or irinotecan	patients aged 18 to 75 years with a histological or cytological diagnosis of advanced or metastatic oesophageal squamous cell carcinoma, had progressed on, or were intolerant to, first-line standard therapy.	228 / 220	high	conclusif	demonstrated 29 % decrease in deaths (OS),deaths (OS) (PE) suggested 31 % decrease in progression or deaths (PFS),progression or deaths (PFS)
	nivolumab alone
	ATTRACTION-3, 2019 Lancet Oncol 2019 Nov;20(11):1506-1517. NCT02569242	RCT	mEC - 2nd line (L2)	Nivolumab	ICC Docetaxel/Paclitaxel	Patients With Unresectable Advanced or Recurrent (squamous or adenosquamous) Esophageal (including the oesophagogastric junction) Cancer who have failed in standard chemotherapies.	210 / 209	high	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) statistically significant 64 % decrease in DCR
	pembrolizumab alone
	KEYNOTE-181, 2020 Journal of Clinical Oncology Journal of Clinical Oncology J Clin Oncol 2020 Dec 10;38(35):4138-4148. Pubmed J Clin Oncol 2021 Nov 3;JCO2100601. ESMO Open. 2022 Feb;7(1):100341. NCT02564263	RCT	mEC - 2nd line (L2)	Pembrolizumab	chemotherapy ICC (paclitaxel, docetaxel, or irinotecan)	Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus/ or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) That Have Progressed After First-Line Standard Therapy	314 / 314	NA	inconclusive	inconclusive 11 % decrease in deaths (OS) (PE) (Pembrolizumab significantly improved OS compared with chemo as second-line therapy for advanced esophageal cancer with PD-L1 CPS ≥10) => no stat plan